Hangzhou Ruipu Chenchuang Technology
A regenerative medicine company leveraging stem cell therapy to address diabetes, with plans to expand its application to other disease areas.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Related Content
Hangzhou Ruipu Chenchuang Technology, operating as ReproGenix Bioscience, is a regenerative medicine company established in 2014, with a strategic focus on developing stem cell-based therapies. The company was co-founded by Professor Hongkui Deng, a distinguished stem cell researcher and Director of the Peking University Stem Cell Research Center; Dr. Lieming Ding, a seasoned pharmaceutical industry leader; and Casey Lou, a serial entrepreneur who serves as CEO. Professor Deng's pioneering work in non-genetic cellular reprogramming technologies provides the scientific foundation for the company's core technology.
ReproGenix is centered on the clinical application of chemically induced pluripotent stem cells (CiPSCs) to address significant unmet medical needs, primarily diabetes. The company's business model involves intensive research and development to bring proprietary cell therapies through clinical trials to commercialization. Its operations encompass a comprehensive platform that integrates research, manufacturing under GMP conditions, and clinical translation. The company's lead product is RGB-5088, an islet cell injection derived from CiPSCs designed for diabetes therapy. This product represents a potential paradigm shift, moving from disease management to a curative-intent therapy.
A landmark achievement for the company was the successful treatment of a type 1 diabetes patient, who became insulin-independent within 75 days of receiving the RGB-5088 transplant, a result that was replicated in subsequent patients. This breakthrough, published in the journal *Cell*, demonstrated the safety and efficacy of the therapy in a pilot clinical study. Following these results, RGB-5088 received Investigational New Drug (IND) approval in China, and a Phase 1 clinical trial has commenced. ReproGenix anticipates starting Phase 2/3 trials in 2026, with a target for a Biologics License Application (BLA) filing in China by 2027. To support its clinical pipeline and bioprocess optimization, the company plans to raise significant capital.
Keywords: regenerative medicine, stem cell therapy, diabetes treatment, chemically induced pluripotent stem cells, CiPSC, islet cell transplantation, cell therapy, biotechnology, Hongkui Deng, Lieming Ding, RGB-5088, clinical trials, insulin independence, type 1 diabetes, advanced therapies, biopharmaceutical, cellular reprogramming